Reviewer's report

**Title:** Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

**Version:** 1  **Date:** 21 May 2010

**Reviewer:** Tomoaki Fujioka

**Reviewer's report:**

The authors reported that EZH2 is independent unfavorable prognostic factor of RCC patients. This study is well designed and includes a large number of samples, and furthermore patients have been followed up for a comparatively long periods. It is interesting that EZH2 is demonstrated as prognostic factor. However, following additional data should be presented.

Major Compulsory Revisions

1. The MSKCC (Memorial Sloan-Kettering Cancer Center) risk categorization is widely accepted as prognostic factor for metastatic RCC. The association between MSKCC risk categorization and EZH2 expression need to be demonstrated.

2. Whereas there is a sentence that non-tumorous kidney tissue was mainly negative for EZH2 expression (page 10, lane 8), no concrete scores were described. Add the data into Table2.

Minor Essential Revisions

None.

Discretionary Revisions

None.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

I declare that I have no competing interests